Produced by enzymatic breakdown of purified pig brain proteins, yielding a mixture of small peptides and amino acids. The claimed mechanism is neurotrophic activity mimicking endogenous factors such as BDNF and GDNF. Because the composition is a mixture rather than a defined entity, mechanistic claims are inherently imprecise, and batch consistency is a live scientific question rather than a manufacturing detail.
Substantially more human data than most neuropeptides here — trials in acute ischaemic stroke, vascular dementia, Alzheimer's disease and traumatic brain injury, conducted largely in Europe, Russia and Asia. Cochrane reviews of stroke have concluded the evidence does not demonstrate benefit and have raised concerns about outcome reporting. It is registered in many countries and rejected by others, which tells you how the evidence reads to different regulators.
Not FDA-approved. Registered in numerous countries across Europe and Asia. Animal-derived biological material.
Extensive marketed use suggests reasonable tolerability. Porcine origin brings immunogenicity and transmissible-agent considerations that synthetic peptides do not have.
Forge Bioenergy does not publish dosing, reconstitution, or administration protocols for any peptide. See our editorial policy for why. If you are considering any substance on this page, that conversation belongs with a licensed physician.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.